Best Grants for Rare Diseases in Connecticut

Stealth Biotherapeutics offers grants and sponsorships aimed at enhancing healthcare education for providers and patient communities. These funding opportunities focus on innovative programs that address rare genetic disorders, neurodegenerative conditions, and ophthalmic disorders. To apply, requests must be submitted 60 days prior to the funding start date, ensuring alignment with the therapeutic interests of the organization while providing valuable insights for healthcare professionals.

Stealth Biotherapeutics is dedicated to supporting innovative programs that enhance disease awareness and therapeutic management. Their charitable contributions focus on accredited institutions, promoting educational initiatives for health care providers and patient communities. Funding is prioritized for unique and cost-effective projects that align with their therapeutic interests, including rare genetic disorders, neurodegenerative diseases, and ophthalmic conditions. By fostering community awareness, they aim to make a significant impact in the healthcare landscape.

The Gerber Foundation offers grants for pediatric research focusing on environmental hazards that affect infants and young children. The foundation seeks projects that provide innovative solutions to health and nutritional challenges faced by this vulnerable population. Grant applications are encouraged from organizations recognized as tax-exempt under Internal Revenue Code 501(c)(3), with an emphasis on research that produces new information to improve practices in infant care and development.

The Gerber Foundation's Novice Researcher Grant aims to enhance the quality of life for infants and young children by funding innovative research in health and nutrition. With a focus on practical solutions that can be rapidly implemented, the grant supports projects addressing everyday challenges faced by young children and their caregivers. Eligible applicants include early-career researchers, with grants capped at $30,000, making it accessible for those looking to contribute to significant advancements in pediatric care.

This funding opportunity from the Patient-Centered Outcomes Research Institute aims to enhance health decision-making through comparative clinical effectiveness research, focusing on critical areas such as cancer, maternal health, and mental health. The initiative encourages robust observational studies that utilize existing data to derive patient-centered insights. Applications must address specific themes approved by PCORI and demonstrate potential benefits to the U.S. healthcare system, thus ensuring relevance and stakeholder engagement in research efforts.

BioMarin offers funding through its donation program focused on improving healthcare and patient advocacy, particularly for rare diseases. Organizations eligible for support include hospitals, accredited providers, and patient advocacy groups. BioMarin prioritizes innovative therapeutic solutions for rare genetic conditions. The company is dedicated to enhancing patient care and education, and it reviews funding requests year-round, although specific deadlines apply for year-end funding. This initiative reflects BioMarin's commitment to addressing unmet medical needs.

The BioMarin Medical Education Grant offers funding for educational activities aimed at enhancing the knowledge and skills of healthcare professionals. Eligible applicants include accredited providers, medical associations, and patient advocacy groups. The grant focuses on supporting initiatives related to rare diseases, ensuring timely access to treatments and education. Applications are accepted year-round, but a minimum of 60 days is required for review prior to events. This commitment underscores BioMarin's dedication to improving patient care and advancing medical knowledge.

The BioMarin Grant aims to support events, activities, and projects that enhance public health and benefit patients with rare diseases. This corporate funder focuses on scientific innovation and provides resources for organizations such as hospitals, universities, and patient advocacy groups. With an emphasis on education and community support, BioMarin encourages applications for funding throughout the year, ensuring timely assistance for eligible projects.

The Lundbeck US Charitable Fund focuses on enhancing brain health through sponsorships that support various initiatives. These sponsorships are available to both non-profit and for-profit organizations, provided they align with Lundbeck's mission. Funds are primarily allocated for educational or awareness events, with an emphasis on community outreach and collaboration to address gaps in care, especially for vulnerable populations. By fostering innovative strategies, the Fund aims to drive meaningful change in the field of brain health.

The Lundbeck US Charitable Fund focuses on enhancing brain health through impactful donations. Established to support organizations dedicated to brain health, it addresses pressing needs by funding innovative strategies and community collaborations, particularly for at-risk populations. The Fund aims to transform lives and improve mental health care, with a commitment to responsible giving. With over 20 organizations supported in 2023, it drives meaningful change in communities affected by brain disorders.

The PCORI Engagement Award: Capacity Building aims to enhance the capacity of patients and stakeholders in patient-centered comparative clinical effectiveness research (CER). Projects can last up to two years with funding up to $300,000. Successful proposals will demonstrate understanding of CER, community engagement, and commitment from stakeholders. The initiative encourages the use of existing tools and resources to foster patient involvement in research processes, aligning with national health priorities and addressing pressing healthcare issues.

The Mike & Sofia Segal Foundation Grant provides vital funding to nonprofit organizations focused on intellectual freedom, medical research for rare diseases, Jewish heritage preservation, elder care, and climate change initiatives. By supporting innovative projects that align with their mission, the foundation aims to uplift communities and foster meaningful societal contributions. Organizations must be 501c-3 compliant and demonstrate a clear plan for engagement with beneficiaries and measurable objectives to be eligible for funding.

The Hope Funds for Cancer Research offers a three-year Postdoctoral Fellowship for innovative research in understanding difficult-to-treat cancers. Candidates with MD, PhD, or equivalent degrees can apply, focusing on novel approaches to cancer mechanisms and treatments. The fellowship provides a stipend starting at $56,000, with annual increases, and a travel grant of $1,500 for conferences. This initiative aims to enhance life expectancy through groundbreaking research in cancer treatment and prevention.

The Patient-Centered Outcomes Research Institute (PCORI) will announce funding for patient-centered comparative clinical effectiveness research (CER) studies focusing on rare diseases. This initiative encourages collaboration and aims to fill critical research gaps affecting approximately 30 million Americans with rare diseases. Applications can request up to $12 million over five years, including coverage for patient care costs. This funding opportunity is set to open on August 12, 2025, with a focus on addressing pressing patient-centered CER questions.

The US Department of Health & Human Services, through the FDA, is funding clinical trials targeting rare neurodegenerative diseases. This initiative aims to enhance treatment options by evaluating the efficacy and safety of new products for both children and adults. By fostering innovative and collaborative trial designs, the FDA seeks to accelerate the approval of new therapies, ultimately benefiting patients with rare conditions and advancing drug development in this critical area.

This funding opportunity announcement (FOA) aims to support research that advances the development of medical products for preventing, diagnosing, treating, or curing ALS and other rare neurodegenerative diseases. The FDA seeks to address critical knowledge gaps and significantly impact these diseases through this initiative, which targets both adult and pediatric populations. By funding these studies, the FDA hopes to inform current and future product development in this vital area of healthcare.